Key Highlights
- Amgen shares closed up 2.94% at $390.02, after the company reported second-quarter results that beat the $5.62 consensus EPS estimate with adjusted EPS of $6.29.
- Revenue of $10.05 billion beat the $9.42 billion estimate, up 9.5% year over year.
- Management raised full-year 2026 adjusted EPS guidance to $22.30 to $23.50, from a prior range of $21.70 to $23.10.
- Full-year sales guidance was lifted to $38.2 billion to $39.4 billion, from a prior range of $37.1 billion to $38.5 billion.
- Investors are continuing to monitor a reported data breach involving patient and proprietary information, alongside offsetting legacy product declines.
What Drove the Close
Amgen (NASDAQ:AMGN) shares closed up 2.94% at $390.02, with a day range of $376.02 to $390.95 on volume of 3.46 million shares, after the company delivered a strong second-quarter earnings beat that exceeded both revenue and profit expectations.
Total revenues increased 10% to $10.1 billion compared with the second quarter of 2025, with product sales growing 9% driven by volume growth. Twenty-two products delivered at least double-digit sales growth, and seventeen products are now annualizing at more than $1 billion based on second-quarter sales. GAAP EPS increased 65% from $2.65 to $4.37, while non-GAAP EPS increased 4% from $6.02 to $6.29, both driven by higher revenues.
The company's six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales. Repatha sales increased 37% to $953 million, EVENITY sales increased 38% to $714 million, and UPLIZNA sales surged 90% to $335 million, while Prolia sales decreased 32% to $759 million as multiple biosimilars have launched globally.
Guidance and Pipeline
Amgen raised full-year 2026 guidance, with total revenues now expected in the range of $38.2 billion to $39.4 billion, up from a prior range of $37.1 billion to $38.5 billion. Non-GAAP EPS guidance was raised to $22.30 to $23.50, up from $21.70 to $23.10, while GAAP EPS guidance was set at $15.80 to $17.08. The company generated $3.5 billion of free cash flow in the quarter, versus $1.9 billion in the prior-year period.
On the pipeline front, Amgen highlighted continued progress for MariTide, its obesity antibody-peptide conjugate, with three Phase 3 studies in type 2 diabetes patients set to begin in 2026, alongside multiple ongoing cardiovascular and metabolic outcome trials. In oncology, IMDELLTRA sales more than doubled to $288 million following European and Chinese regulatory approvals, though the company also disclosed that a subcutaneous blinatumomab study has paused enrollment following a partial clinical hold by the FDA, with discussions underway on a path forward.
Investors continue to monitor a reported data breach involving patient and proprietary information, even as the company's underlying business performance remained strong. Amgen's market capitalization stood at $210.50 billion, with a trailing price-to-earnings ratio of 17.65 and a dividend yield of 2.51%. The stock's 52-week range spans $269.77 to $398.00.
Conclusion
Amgen's strong second-quarter beat and raised full-year guidance reflect broad-based growth across its key product portfolio, even as investors continue to weigh a reported data breach and a clinical hold on one of its oncology programs. With MariTide advancing through Phase 3 development in obesity and diabetes, the stock's trajectory will likely depend on continued execution against its raised guidance and further pipeline progress.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...